Don’t miss this one.
Jamal Rushdy, President & CEO of Miach Orthopaedics, joins us to talk about defining the standard of care for orthopedic tissue preservation and restoration.
For 30+ years, a torn ACL meant reconstruction: harvest a graft, drill tunnels, accept donor-site morbidity, and hope the knee holds up long-term.
Miach’s BEAR Implant flips that model. It is a collagen scaffold hydrated with the patient’s own blood that lets the torn ACL heal itself instead of replacing it.
What we’ll cover on the Zoom:
How BEAR actually works in the notch — and why the tibial stump matters
Level 1 data vs. reconstruction: comparable IKDC and laxity, better hamstring strength, and a label update on reduced PTOA risk
Scaling from De Novo (2020) to kids/partial tears (2025) to 9,000+ patients and 750+ surgeons
What changes when you sell restoration instead of reconstruction: surgeon education, rehab protocol, VAC story, and commercial playbook
Jamal’s take after ~30 years in sports med / regen (Tornier, DJO/Enovis, Collagen Solutions, Arcuro) on where connective-tissue restoration goes next
Event Details:
Date: Thursday, September 17
Time: 3:00 PM EST (~60 minutes, live Q&A)
Two...
